Premium
VMAT2 quantitation by PET as a biomarker for β‐cell mass in health and disease
Author(s) -
Freeby M.,
Goland R.,
Ichise M.,
Maffei A.,
Leibel R.,
Harris P.
Publication year - 2008
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2008.00943.x
Subject(s) - biomarker , disease , medicine , computational biology , chemistry , biology , biochemistry
The common pathology underlying both type 1 and type 2 diabetes (T1DM and T2DM) is insufficient β‐cell mass (BCM) to meet metabolic demands. An important impediment to the more rapid evaluation of interventions for both T1DM and T2DM lack of biomarkers of pancreatic BCM. A reliable means of monitoring the mass and/or function of β‐cells would enable evaluation of the progression of diabetes as well as the monitoring of pharmacologic and other interventions. Recently, we identified a biomarker of BCM that is quantifiable by positron emission tomography (PET). PET is an imaging technique which allows for non‐invasive measurements of radioligand uptake and clearance, is sensitive in the pico‐ to nanomolar range and of which the results can be deconvoluted into measurements of receptor concentration. For BCM estimates, we have identified VMAT2 (vesicular monoamine transporter type 2) as a biomarker and [ 11 C] DTBZ (dihydrotetrabenazine) as the transporter’s ligand. VMAT2 is highly expressed in β‐cells of the human pancreas relative to other cells of the endocrine and exocrine pancreas. Thus measurements of [ 11 C] DTBZ in the pancreas provide an indirect measurement of BCM. Here we summarize our ongoing efforts to validate the clinical utility of this non‐invasive approach to real‐time BCM measurements